Karyopharm receives FDA Track Designation for selinexor

Karyopharm Therapeutics announced that the United States Food and Drug Administration FDA has granted Fast Track Designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.